Abstract
High-dose cytarabine is one of the major components of the conditioning regimen for hematopoietic stem cell transplantation (HSCT), and frequently causes severe oral mucositis. We have recently demonstrated that cytarabine is excreted into the saliva in patients receiving high-dose cytarabine, and proposed that it might locally and directly contribute to the development of oral mucositis. Therefore, this study was performed to assess whether removing the excreted cytarabine in the saliva by intensive mouth rinse during high-dose cytarabine infusion could reduce the incidence of oral mucositis. Fifteen patients with hematologic malignancies undergoing allogeneic HSCT who received total body irradiation (12 Gy) and high-dose cytarabine at a dose of 3 g/m2 every 12 h for 4 days as a conditioning were evaluated. Patients were instructed to rinse their mouths using ice-cold water every 10 min, starting simultaneously with the 2-h cytarabine infusion and continuing up to 1 h after completion of each infusion. Oral mucositis was graded on a daily basis according to the National Cancer Institute, Common Toxicity Criteria. Thirty-five patients who previously underwent the same conditioning without mouth rinse served as controls. The incidence of Grades 2–3 and Grade 3 oral mucositis was significantly reduced in patients who performed mouth rinse as compared with the controls (40 vs. 80%, P = 0.009; 0 vs. 25. 7%, P = 0.02). In conclusion, mouth rinse during and shortly after high-dose cytarabine infusion could be an effective and inexpensive measure in reducing the incidence of moderate to severe oral mucositis caused by high-dose cytarabine. This finding strongly suggests the role of cytarabine excretion in the saliva in the development of cytarabine-associated oral mucositis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Filicko J, Lazarus HM, Flomberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone Marrow Transplant. 2003;31:1–10. doi:10.1038/sj.bmt.1703776.
Coccia PF, Strandjord SE, Warkentin PI, Cheung NK, Gordon EM, Novak LJ, et al. High-dose cytosine arabinoside and fractionated total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood. 1988;71:888–93.
Riddell S, Appelbaum FR, Buckner CD, Stewart P, Clift R, Sanders J, et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol. 1988;6:576–82.
Kamani N, Bayever E, August CS, Bunin N, Goldwein JW, D’Angio GJ. Fractionated toral-body irradiation preceding high-dose cytosine arabinoside as a preparative regimen for bone marrow transplantation in children with acute leukemia. Med Pediatr Oncol. 1995;25:179–84. doi:10.1002/mpo.2950250304.
Takahashi S, Okamoto SI, Shirafuji N, Ikebuchi K, Tani K, Shimane M, et al. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. Bone Marrow Transplant. 1994;13:239–45.
Okamoto S, Takahashi S, Wakui M, Ishida A, Tanosaki R, Ikeda Y, et al. Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. Br J Haematol. 1999;104:569–73. doi:10.1046/j.1365-2141.1999.01205.x.
Mori T, Yamazaki R, Nakazato T, Aisa Y, Enoki S, Arai M, et al. Excretion of cytosine arabinoside in saliva after its administration at high doses. Anticancer Drugs. 2006;17:597–8. doi:10.1097/00001813-200606000-00015.
Mori T, Aisa Y, Yokoyama A, Nakazato T, Yamazaki R, Shimizu T, et al. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience. Bone Marrow Transplant. 2007;39:217–21. doi:10.1038/sj.bmt.1705578.
Karthaus M, Rosenthal C, Ganse A. Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis—are there new strategies? Bone Marrow Transplant. 1999;24:1095–108. doi:10.1038/sj.bmt.1702024.
Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol. 1991;9:449–52.
Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of fluorouracil-related stomatitis. Cancer. 1993;72:2234–8. doi:10.1002/1097-0142(19931001)72:7<2234::AID-CNCR2820720728>3.0.CO;2-N.
Meloni G, Capria S, Proia A, Trisolini SM, Mandelli F. Ice pops to prevent melphalan-induced stomatitis. Lancet. 1996;347:1691–2. doi:10.1016/S0140-6736(96)91518-4.
Dumonet C, Sonnet A, Bastion Y, Salles G, Espinouse D, Coiffier B. Prevention of high dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant. 1994;3:492–4.
Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A, et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2005;13:266–9. doi:10.1007/s00520-004-0726-y.
Mori T, Yamazaki R, Aisa Y, Nakazato T, Kudo M, Yashima T, et al. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2006;14:392–5. doi:10.1007/s00520-005-0016-3.
Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995;75:11–7. doi:10.1002/1097-0142(19950101)75:1<11::AID-CNCR2820750104>3.0.CO;2-N.
Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17:2412–8.
Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thürlimann B, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the international breast cancer study group trial VII. J Clin Oncol. 2000;18:1412–22.
Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1(Suppl 2):18–24.
Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JH. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J Clin Oncol. 1984;2:545–9.
Grümayer ER, Schmidmeier W, Panzer S, Gadner H. Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia. Blut. 1986;53:309–14. doi:10.1007/BF00320890.
Vogler WR, Preisler HD, Winton EF, Gottlieb AJ, Goldberg J, Brennan J, et al. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a leukemia intergroup study. Cancer Treat Rep. 1986;70:455–9.
Barrios NJ, Tebbi CK, Freeman AI, Brecher ML. Toxicity of high dose Ara-C in children and adolescents. Cancer. 1987;60:165–9. doi:10.1002/1097-0142(19870715)60:2<165::AID-CNCR2820600207>3.0.CO;2-G.
Author information
Authors and Affiliations
Corresponding author
Additional information
T. Mori and K. Hasegawa equally contributed to this work.
About this article
Cite this article
Mori, T., Hasegawa, K., Okabe, A. et al. Efficacy of mouth rinse in preventing oral mucositis in patients receiving high-dose cytarabine for allogeneic hematopoietic stem cell transplantation. Int J Hematol 88, 583–587 (2008). https://doi.org/10.1007/s12185-008-0181-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-008-0181-5